Annals of Oncology, 1569-8041

Journal

More filtering options
  1. 2021
  2. Adjuvant imatinib for GIST: duration likely matters

    M. Eriksson & H. Joensuu, 2021, In: Annals of Oncology. 32, 4, p. 434-436

    Research output: Contribution to journalDebate/Note/Editorial

  3. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M. Dreyling, M. Ghielmini, S. Rule, G. Salles, M. Ladetto, S. H. Tonino, K. Herfarth, J. F. Seymour, M. Jerkeman & ESMO Guidelines Committee ESMO Guidelines Committee, 2021, In: Annals of oncology : official journal of the European Society for Medical Oncology. 32, 3, p. 298-308 11 p.

    Research output: Contribution to journalArticle

  4. 2019
  5. The role of plasma microseminoprotein-beta in prostate cancer: An observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition

    K. Smith Byrne, P. N. Appleby, T. J. Key, M. V. Holmes, G. K. Fensom, A. Agudo, E. Ardanaz, H. Boeing, H. B. Bueno-De-Mesquita, M. D. Chirlaque, R. Kaaks, N. Larranãga, D. Palli, A. Perez-Cornago, J. R. Quirós, F. Ricceri, M. J. Sánchez, G. Tagliabue, K. K. Tsilidis, R. Tumino & 5 others, R. T. Fortner, P. Ferrari, E. Riboli, H. Lilja & R. C. Travis, 2019 Jun 1, In: Annals of Oncology. 30, 6, p. 983-989 7 p., mdz121.

    Research output: Contribution to journalArticle

  6. Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative

    J. B. Sørensen, S. Ekman, O. T. Brustugun, P. Horvat, D. Patel, M. Rosenlund, A. Mette Kejs, A. Juarez-Garcia, M. Daumont, L. Lacoin, J. R. Penrod, J. C. O'Donnell & M. Planck, 2019 Apr, In: Annals of Oncology. 30, Suppl 2, p. ii16-ii17

    Research output: Contribution to journalPublished meeting abstract

  7. Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative

    S. Ekman, J. B. Sørensen, O. T. Brustugun, P. Horvat, D. Patel, M. Rosenlund, A. Mette Kejs, A. Juarez-Garcia, M. Daumont, L. Lacoin, J. R. Penrod, J. C. O'Donnell & M. Planck, 2019 Apr, In: Annals of Oncology. 30, Suppl 2, p. ii17 1 p.

    Research output: Contribution to journalPublished meeting abstract

  8. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

    A. Matikas, T. Foukakis, V. Moebus, R. Greil, N. O. Bengtsson, G. G. Steger, M. Untch, H. Johansson, M. Hellström, P. Malmström, M. Gnant, S. Loibl & J. Bergh, 2019, In: Annals of oncology : official journal of the European Society for Medical Oncology. 30, 1, p. 109-114 6 p.

    Research output: Contribution to journalArticle

  9. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    F. Cardoso, S. Kyriakides, S. Ohno, F. Penault-Llorca, P. Poortmans, I. T. Rubio, S. Zackrisson & E. Senkus, 2019, In: Annals of Oncology. 30, 8, p. 1194-1220 27 p.

    Research output: Contribution to journalArticle

  10. Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment

    K. Weibring, C. Nord, O. Ståhl, J. Eberhard, K. Sandberg, H. Johansson, S. Arver, A. Giwercman & G. Cohn-Cedermark, 2019, In: Annals of oncology : official journal of the European Society for Medical Oncology. 30, 4, p. 604-611 8 p.

    Research output: Contribution to journalArticle

  11. Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

    H. Zuo, P. M. Ueland, Midttun, G. S. Tell, A. Fanidi, W. Zheng, X. Shu, Y. Xiang, J. Wu, R. Prentice, M. Pettinger, C. A. Thomson, G. G. Giles, A. Hodge, Q. Cai, W. J. Blot, M. Johansson, J. Hultdin, K. Grankvist, V. L. Stevens & 29 others, M. L. McCullough, S. J. Weinstein, D. Albanes, R. G. Ziegler, N. D. Freedman, N. E. Caporaso, A. Langhammer, K. Hveem, M. Næss, J. E. Buring, I. Lee, J. M. Gaziano, G. Severi, X. Zhang, M. J. Stampfer, J. Han, A. Zeleniuch-Jacquotte, L. L. Marchand, J. Yuan, R. Wang, W. Koh, Y. Gao, U. Ericson, K. Visvanathan, M. R. Jones, C. Relton, P. Brennan, M. Johansson & A. Ulvik, 2019, In: Annals of Oncology. 30, 3, p. 478-485 8 p.

    Research output: Contribution to journalArticle

  12. 2018
  13. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P. G. Casali & et al. et al., 2018 Oct 1, In: Annals of Oncology. 29, p. iv68-iv78

    Research output: Contribution to journalArticle

  14. Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers

    Dominik Glodzik, Colin A Purdie, Inga Hansine Rye, Peter T Simpson, Johan Staaf, Paul N. Span, Hege Russnes & Serena Nik-Zainal, 2018 Sep 15, In: Annals of Oncology. 30252041.

    Research output: Contribution to journalArticle

  15. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists

    Kari Nielsen & Reader study level-I and level-II Groups Reader study level-I and level-II Groups , 2018 Aug 1, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, 8, p. 1836-1842 7 p.

    Research output: Contribution to journalArticle

  16. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy

    Michael Friedlander, J. Rau, C. K. Lee, W. Meier, A. Lesoin, J. W. Kim, A. Poveda, M. Buck, G. Scambia, M. Shimada, F. Hilpert, M. T. King, P. Debruyne, A. Bologna, S. Malander, B. J. Monk, E. Petru, P. Calvert, T. J. Herzog, C. Barrett & 1 others, A. du Bois, 2018 Mar 1, In: Annals of Oncology. 29, 3, p. 737-743 7 p., mdx821.

    Research output: Contribution to journalArticle

  17. Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: The RASTEN trial

    L. Ek, E. Gezelius, B. Bergman, P. O. Bendahl, H. Anderson, J. Sundberg, M. Wallberg, U. Falkmer, S. Verma, M. Belting & Swedish Lung Cancer Study Group (SLUSG) Swedish Lung Cancer Study Group (SLUSG), 2018 Feb 1, In: Annals of Oncology. 29, 2, p. 398-404

    Research output: Contribution to journalArticle

  18. The genomic grade index predicts postoperative clinical outcome in patients with soft-tissue sarcoma

    F. Bertucci, A. De Nonneville, P. Finetti, D. Perrot, M. Nilbert, A. Italiano, A. Le Cesne, K. M. Skubitz, J. Y. Blay & D. Birnbaum, 2018 Feb 1, In: Annals of Oncology. 29, 2, p. 459-465

    Research output: Contribution to journalArticle

  19. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma

    Y. L. Kwong, S. J. Kim, E. Tse, S. Y. Oh, J. Y. Kwak, H. S. Eom, Y. R. Do, Y. C. Mun, S. R. Lee, H. J. Shin, C. Suh, S. S. Chuang, Y. S. Lee, S. T. Lim, K. Izutsu, R. Suzuki, T. Relander, F. d'Amore, N. Schmitz, A. Jaccard & 1 others, W. S. Kim, 2018 Jan 1, In: Annals of Oncology. 29, 1, p. 256-263 mdx684.

    Research output: Contribution to journalArticle

  20. Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer

    T. Loughman, A. Chan-Ju Wang, P. Dynoodt, B. Fender, C. Lopez Ruiz, S. Barron, S. Stapleton, D. O'Leary, A. Fabre, C. Quinn, B. Nodin, K. Jirstrom, A. Bracken & W. M. Gallagher, 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, Suppl. 8, p. viii65

    Research output: Contribution to journalArticle

  21. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P. G. Casali, S. Bielack, N. Abecassis, H. T. Aro, S. Bauer, R. Biagini, S. Bonvalot, I. Boukovinas, J. V.M.G. Bovee, B. Brennan, T. Brodowicz, J. M. Broto, L. Brugières, A. Buonadonna, E. De Álava, A. P. Dei Tos, X. G. Del Muro, P. Dileo, C. Dhooge, M. Eriksson & 32 others, F. Fagioli, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A. M. Frezza, N. Gaspar, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R. L. Haas, B. Hassan, S. Hecker-Nolting, P. Hohenberger, R. Issels, H. Joensuu, R. L. Jones, I. Judson, P. Jutte, S. Kaal, L. Kager, B. Kasper, K. Kopeckova, D. A. Krákorová, R. Ladenstein, A. Le Cesne, I. Lugowska, O. Merimsky, ESMO Guidelines Committee ESMO Guidelines Committee & PaedCan PaedCan, 2018, In: Annals of Oncology. 29, p. iv79-iv95

    Research output: Contribution to journalArticle

  22. Intermediate prognosis in metastatic germ cell tumors (IPGCT): Outcome and prognostic stratification

    C. Seidel, K. G. Daugaard, A. Tryakin, A. Necchi, G. Cohn Cedermark, O. Ståhl, M. Hentrich, M. Brito, C. Albany, F. Taza, A. Gerl, K. Oechsle, C. Oing & C. Bokemeyer, 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii325

    Research output: Contribution to journalArticle

  23. 2017
  24. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    A Hochhaus, Susanne Saussele, G Rosti, Francois-Xavier Mahon, J. J.W.M. Janssen, H. Hjorth-Hansen, J. Richter, Christian Buske & ESMO Guidelines Committee ESMO Guidelines Committee, 2017, In: Annals of Oncology. 28, p. iv41-iv51

    Research output: Contribution to journalArticle

  25. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M Dreyling, E Campo, O Hermine, M. Jerkeman, S. Le Gouill, Simon Rule, Ofer Shpilberg, J. Walewski, M. Ladetto & on behalf of the ESMO Guidelines Committee on behalf of the ESMO Guidelines Committee, 2017, In: Annals of Oncology. 28, p. iv62-iv71

    Research output: Contribution to journalArticle

  26. 2016
  27. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: A report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)

    Torgrim Tandstad, Olof Ståhl, O. Dahl, H. S. Haugnes, U. Håkansson, A. Karlsdottir, A. Kjellman, C. W. Langberg, A. Laurell, J. Oldenburg, A. Solberg, K. Söderström, U. Stierner, E. Cavallin-Ståhl, R. Wahlqvist, N. Wall & G. Cohn-Cedermark, 2016 Jul 1, In: Annals of Oncology. 27, 7, p. 1299-1304 6 p., mdw164.

    Research output: Contribution to journalArticle

  28. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

    Helga Hagman, Jan-Erik Frödin, Åke Berglund, Jan Sundberg, Lene Vestermark, Maria Albertsson, Eva Fernebro & Anders Johnsson, 2016 Jan, In: Annals of Oncology. 27, 1, p. 140-147

    Research output: Contribution to journalArticle

  29. Cancer mortality in cohorts of workers in the European rubber manufacturing industry first employed since 1975.

    M Boniol, A Koechlin, B Świątkowska, T Sorahan, J Wellmann, D Taeger, Kristina Jakobsson, E Pira, P Boffetta, C La Vecchia, C Pizot & P Boyle, 2016, In: Annals of Oncology. 27, 5, p. 933-941

    Research output: Contribution to journalArticle

  30. Health care resource use and costs of cancer-associated thrombosis in Sweden

    H. Norrlid, M. V. Holm, J. Norlin, P. Svensson & G. Ragnarson Tennvall, 2016, In: Annals of Oncology. 27, Suppl. 6, p. vi356

    Research output: Contribution to journalArticle

  31. The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)

    S. Chowdhury, A. J. Birtle, A. Bjartell, L. A.M. Costa, S. Feyerabend, L. Galli, E. Kalinka-Warzocha, G. Kramer, J. P.Maroto Rey, N. Lumen, V. B. Matveev, T. Paiss, D. Spaeth, L. Antoni, E. Klumper, R. Wapenaar & E. Lee, 2016, In: Annals of Oncology. 27, Suppl. 6, p. vi253

    Research output: Contribution to journalArticle

  32. 2015
  33. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.

    J S Whelan, S S Bielack, N Marina, S Smeland, G Jovic, J M Hook, M Krailo, J Anninga, T Butterfass-Bahloul, T Böhling, G Calaminus, M Capra, C Deffenbaugh, C Dhooge, Mikael Eriksson, A M Flanagan, H Gelderblom, A Goorin, R Gorlick, G Gosheger & 21 others, R J Grimer, K S Hall, K Helmke, P C Hogendoorn, G Jundt, L Kager, T Kuehne, C Lau, G D Letson, J Meyer, P Meyers, C Morris, H Mottl, H Nadel, R Nagarajan, R L Randall, P Schomberg, R Schwarz, L A Teot, M R Sydes & M Bernstein, 2015, In: Annals of Oncology. 26, 2, p. 407-414

    Research output: Contribution to journalArticle

  34. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival

    N. P. Tobin, J. C. Harrell, J. Lovrot, S. Egyhazi Brage, M. Frostvik Stolt, L. Carlsson, Z. Einbeigi, B. Linderholm, Niklas Loman, Martin Malmberg, T. Walz, Mårten Fernö, C. M. Perou, J. Bergh, T. Hatschek & L. S. Lindstrom, 2015, In: Annals of Oncology. 26, 1, p. 81-88

    Research output: Contribution to journalArticle

  35. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    E Senkus, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, E Rutgers, Sophia Zackrisson & F Cardoso, 2015, In: Annals of Oncology. 26, p. V8-V30

    Research output: Contribution to journalArticle

  36. 2014
  37. 32p * biomarkers and molecular subtypes in primary breast tumors and metastases: associations with liver metastases and outcome.

    Siker Kimbung, A Kovács, Ida Johansson, A Danielsson, Pär-Ola Bendahl, Z Einbeigi, Mårten Fernö, T Hatschek & Ingrid Hedenfalk, 2014, In: Annals of Oncology. 25 Suppl 1, May, p. i11-i12

    Research output: Contribution to journalArticle

  38. 37p * androgen receptor expression in a population-based prospective breast cancer cohort.

    Karin Elebro, Signe Borgquist, Maria Simonsson, Andrea Markkula, Carsten Rose, Christian Ingvar & Helena Jernström, 2014, In: Annals of Oncology. 25 Suppl 1, May, p. i13

    Research output: Contribution to journalPublished meeting abstract

  39. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

    Mikael Eriksson & The ESMO/European Sarcoma Network Working Group The ESMO/European Sarcoma Network Working Group, 2014, In: Annals of Oncology. 25, p. iii113-iii123

    Research output: Contribution to journalArticle

  40. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype

    M. Fallah, Xiangdong Liu, Jianguang Ji, Asta Försti, Kristina Sundquist & Kari Hemminki, 2014, In: Annals of Oncology. 25, 7, p. 1397-1404

    Research output: Contribution to journalArticle

  41. One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.

    T Tandstad, Olof Ståhl, Ulf Håkansson, O Dahl, H S Haugnes, O H Klepp, C W Langberg, A Laurell, J Oldenburg, A Solberg, K Söderström, Eva Cavallin-Ståhl, U Stierner, R Wahlquist, N Wall & G Cohn-Cedermark, 2014, In: Annals of Oncology. 25, 11, p. 2167-2172

    Research output: Contribution to journalArticle

  42. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

    H. Bonnefoi, S. Litiere, M. Piccart, G. MacGrogan, P. Fumoleau, E. Brain, T. Petit, P. Rouanet, J. Jassem, C. Moldovan, A. Bodmer, K. Zaman, T. Cufer, M. Campone, E. Luporsi, Per Malmström, G. Werutsky, J. Bogaerts, J. Bergh & D. A. Cameron, 2014, In: Annals of Oncology. 25, 6, p. 1128-1136

    Research output: Contribution to journalArticle

Previous 1 2 3 Next